A range of new mental health treatments are available to Western medicine, and practitioners are figuring out how to use them effectively. Matt Brockmeier, co-founder and chief legal officer at Entheogyn and of counsel at Antithesis Law, joins Rebecca Nicholson, foundation director and wellness advisor at Prime Quadrant, to explore this evolving landscape with McGuireWoods partner and host Geoff Cockrell.
Matt discusses the tension between state and federal laws shaping access to psychedelics and controlled substances, while Rebecca contrasts the investment dynamics of cannabis versus psychedelics, emphasizing mental health over recreation. They examine specialized investor appetite, the medical community’s evolving response and the ancillary wellness modalities supporting comprehensive mental health transformation.
Connect and Learn More
☑️ Rebecca Nicholson | LinkedIn
☑️ Prime Quadrant
☑️ Matt Brockmeier | LinkedIn
☑️ Entheogyn
☑️ Geoff Cockrell | LinkedIn
☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X
☑️ Subscribe Apple Podcasts | Spotify | Amazon Music
This podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.
